197 related articles for article (PubMed ID: 21562572)
21. Role of fibroblast-derived factors in the pathogenesis of melasma.
Byun JW; Park IS; Choi GS; Shin J
Clin Exp Dermatol; 2016 Aug; 41(6):601-9. PubMed ID: 27416970
[TBL] [Abstract][Full Text] [Related]
22. Exploring pathways for sustained melanogenesis in facial melasma: an immunofluorescence study.
Espósito ACC; Brianezi G; de Souza NP; Miot LDB; Marques MEA; Miot HA
Int J Cosmet Sci; 2018 Aug; 40(4):420-424. PubMed ID: 29846953
[TBL] [Abstract][Full Text] [Related]
23. Melanocyte stem cells express receptors for canonical Wnt-signaling pathway on their surface.
Yamada T; Akamatsu H; Hasegawa S; Inoue Y; Date Y; Mizutani H; Yamamoto N; Matsunaga K; Nakata S
Biochem Biophys Res Commun; 2010 Jun; 396(4):837-42. PubMed ID: 20450888
[TBL] [Abstract][Full Text] [Related]
24. Morphologic changes and the expression of alpha-melanocyte stimulating hormone and melanocortin-1 receptor in melasma lesions: a comparative study.
Miot LD; Miot HA; Polettini J; Silva MG; Marques ME
Am J Dermatopathol; 2010 Oct; 32(7):676-82. PubMed ID: 20534990
[TBL] [Abstract][Full Text] [Related]
25. Melanocyte activation and skin barrier disruption induced in melasma patients after 1064 nm Nd:YAG laser treatment.
Gao YL; Jia XX; Wang M; Hua Y; Zheng H; Xiang WZ; Song XZ
Lasers Med Sci; 2019 Jun; 34(4):767-771. PubMed ID: 30302596
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-5110 regulates pigmentation by cotargeting melanophilin and WNT family member 1.
Yang S; Liu B; Ji K; Fan R; Dong C
FASEB J; 2018 Oct; 32(10):5405-5412. PubMed ID: 29733692
[TBL] [Abstract][Full Text] [Related]
27. CKIepsilon/discs overgrown promotes both Wnt-Fz/beta-catenin and Fz/PCP signaling in Drosophila.
Klein TJ; Jenny A; Djiane A; Mlodzik M
Curr Biol; 2006 Jul; 16(13):1337-43. PubMed ID: 16824922
[TBL] [Abstract][Full Text] [Related]
28. MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3.
Revet I; Huizenga G; Koster J; Volckmann R; van Sluis P; Versteeg R; Geerts D
Cancer Lett; 2010 Mar; 289(2):195-207. PubMed ID: 19815336
[TBL] [Abstract][Full Text] [Related]
29. β-Catenin-dependent pathway activation by both promiscuous "canonical" WNT3a-, and specific "noncanonical" WNT4- and WNT5a-FZD receptor combinations with strong differences in LRP5 and LRP6 dependency.
Ring L; Neth P; Weber C; Steffens S; Faussner A
Cell Signal; 2014 Feb; 26(2):260-7. PubMed ID: 24269653
[TBL] [Abstract][Full Text] [Related]
30. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates.
Thiele S; Rauner M; Goettsch C; Rachner TD; Benad P; Fuessel S; Erdmann K; Hamann C; Baretton GB; Wirth MP; Jakob F; Hofbauer LC
J Cell Biochem; 2011 Jun; 112(6):1593-600. PubMed ID: 21344486
[TBL] [Abstract][Full Text] [Related]
31. The Wnt5a/Ror2 noncanonical signaling pathway inhibits canonical Wnt signaling in K562 cells.
Yuan Y; Niu CC; Deng G; Li ZQ; Pan J; Zhao C; Yang ZL; Si WK
Int J Mol Med; 2011 Jan; 27(1):63-9. PubMed ID: 21069266
[TBL] [Abstract][Full Text] [Related]
32. Co-localization of inducible nitric oxide synthase and phosphorylated Akt in the lesional skins of patients with melasma.
Jo HY; Kim CK; Suh IB; Ryu SW; Ha KS; Kwon YG; Kim YM
J Dermatol; 2009 Jan; 36(1):10-6. PubMed ID: 19207431
[TBL] [Abstract][Full Text] [Related]
33. Wnt5a signaling controls cytokinesis by correctly positioning ESCRT-III at the midbody.
Fumoto K; Kikuchi K; Gon H; Kikuchi A
J Cell Sci; 2012 Oct; 125(Pt 20):4822-32. PubMed ID: 22825874
[TBL] [Abstract][Full Text] [Related]
34. Wnts grasp the WIF domain of Wnt Inhibitory Factor 1 at two distinct binding sites.
Kerekes K; Bányai L; Patthy L
FEBS Lett; 2015 Oct; 589(20 Pt B):3044-51. PubMed ID: 26342861
[TBL] [Abstract][Full Text] [Related]
35. cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.
Bazhin AV; Tambor V; Dikov B; Philippov PP; Schadendorf D; Eichmüller SB
Cell Mol Life Sci; 2010 Mar; 67(5):817-28. PubMed ID: 19946729
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and possible mechanisms of topical tranexamic acid in melasma.
Kim SJ; Park JY; Shibata T; Fujiwara R; Kang HY
Clin Exp Dermatol; 2016 Jul; 41(5):480-5. PubMed ID: 27135282
[TBL] [Abstract][Full Text] [Related]
37. Regulation of focal adhesion dynamics by Wnt5a signaling.
Matsumoto S; Kikuchi A
Methods Mol Biol; 2012; 839():215-27. PubMed ID: 22218904
[TBL] [Abstract][Full Text] [Related]
38. The vascular characteristics of melasma.
Kim EH; Kim YC; Lee ES; Kang HY
J Dermatol Sci; 2007 May; 46(2):111-6. PubMed ID: 17363223
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a Wnt-binding site of the WIF-domain of Wnt inhibitory factor-1.
Bányai L; Kerekes K; Patthy L
FEBS Lett; 2012 Sep; 586(19):3122-6. PubMed ID: 22986341
[TBL] [Abstract][Full Text] [Related]
40. Wnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type 1 interferon.
Romanowska M; Evans A; Kellock D; Bray SE; McLean K; Donandt S; Foerster J
PLoS One; 2009; 4(4):e5354. PubMed ID: 19399181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
